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ABSTRACT 
Over 75% of people infected with HIV live in countries where health resources are very limited for the diagnosis and 
biological monitoring of people infected by the virus. In resource-limited settings, the use of DBS is a valuable alterna- 
tive. It has provided technical and economical alternative to the collection of blood in the tubes for testing HIV infec- 
tion. The DBS can be kept for over a year, it is economical in storage space and facilitates storage conditions because it 
can be stored at room temperature. It is more discreet and easier to carry over liquid samples that require tubes and 
other appropriate materials. The amount is sufficient for certain analyses of DNA generally, but may be insufficient for 
the analysis of viral RNA if the viral load is low. Its disadvantage is often associated with small amounts of blood col- 
lected available for testing, and the difficulties encountered in laboratories to extract the maximum possibilities without 
material contamination. DBS can be stored at room temperature (25˚C - 35˚C), at 4˚C, −20˚C or even −70˚C. With PCR, 
the DBS is a suitable medium for the diagnosis of patients infected with HIV, virological monitoring by the VL and 
even analyzing viral genotype. It is a handy stand for the collection, transport and analyses of biological monitoring of 
HIV infection. It is indeed very suitable for environments with limited accessibility where it is difficult for specialized 
laboratories to monitor these patients. The DBS is suitable for resource-limited settings. 
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1. Introduction of DBS in Biological  
Monitoring of HIV Infection 
It has been estimated that over 34 million people infected 
with HIV in 2012 [1]. Over 75% of these people live in 
countries where health resources are very limited for the 
diagnosis and biological monitoring of victims [1]. Hos- 
pitals and laboratories are, for the most part, limited and 
under-equipped to overcome the problem of diagnosis 
and monitoring of HIV infection. Logistical difficulties 
such as transport of blood samples and respect for the 
cold chain make it difficult to monitor patients who live 
far from specialized centers. 
The diagnosis of HIV infection is often limited for Ra- 
pid Diagnostic Tests (RDTs) to monitor HIV-infected pa- 
tients with biochemical, serological and CD4/CD8 to 
infection [2]. PCR standard diagnostic tool and biologi- 
cal monitoring of HIV infection are hardly accessible 
even in large hospitals [1,3]. Cost, lack of qualified staffs 
and a proper system maintenance staff, unstable power 
supply systems, transport and storage of samples are 
some parameters that make its handling difficult in some 
areas. 
Although WHO has recommended the use of clinical 
monitoring and counting of CD4 lymphocytes for re- 
source-limited settings, several studies have demonstrat- 
ed that monitoring underestimated the impact of virolo- 
gical failure [4-6]. Therefore patients are at risk of poor 
monitoring and miss-treatment. It was therefore recom- 
mended to explore the feasibility of viral load (VL) in 
these environments. 
Used for over 50 years [7], the Dried Blood Spot (DBS) 
or blotting paper remains a technical and economical al- *Corresponding author. 
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ternative to the collection of blood in the tubes for test- 
ing for HIV infection. The method of collecting blood 
from veins in the tubes is difficult to manage in resource- 
limited settings. Sampling, sample storage are in good 
conditions (2˚C - 8˚C) to avoid losses, transport samples 
in the time and in the right conditions (respect for the 
cold chain) to the center or specialized laboratory, so that 
these samples are processes. With the PCR technic, sam- 
ples are to be taken care of very quickly to limit losses of 
the nucleic acid. The DBS technique allows sending the 
collected samples easily to specialized laboratories lim- 
iting constraints of storage and transportation condition. 
DBS can be prepared from any environment in accor- 
dance with good laboratory standards (Good Laboratory 
Practice-GLP) and sent even by local postal services. 
2. Advantages  
DBS can be kept in its original state for several years. It 
is less invasive, economical storage space and facilitates 
storage conditions because it can be stored at room tem- 
perature. It also makes it easy to collect drops of blood 
from a finger prick or heel of infants in the maternity 
ward or in remote areas with limited accessibility. 
It requires a small amount of blood, it is more discreet 
and easier to carry over liquid samples that require tubes 
and other appropriate materials [8]. Its delivery in spe- 
cialized, local or international laboratories for diagnostic 
analysis or research is easier and faster [9]. Samples can 
be sent out by mail in a sealed box without worrying 
about losing the quality of the sample. It is less invasive 
in the length of its use, the sample for analysis. It is also 
less expensive compared to the collection of liquid blood 
in tubes, tube prices and staff for collection. Contamina- 
tion risks to health personnel are also reduced with the 
use of DBS [10]. The small amount, ease of sample col- 
lection in hospital and non-hospital, ease of storage and 
transport of samples and low cost make that this method 
of collection is ideal for resource-limited settings [10- 
12]. 
Although the amount is limited, the quality of genetic 
material that is extracted from the DBS is comparable to 
that extracted from whole blood and/or its derivatives. So 
far, several protocols have been adapted for the extrac- 
tion of genetic material from the DBS. These are specific 
protocols for extraction of DNA and RNA. 
To optimize the performance of the extraction of RNA, 
it was developed two variants of DBS: The Dried Spot 
Serum (DSS) [13-16] and Dried Plasma Spot (DPS) 
[15-21]. With these variants, whole blood is first centri- 
fuged and only serum or plasma is then deposited on the 
substrate, this limits the presence of DNA in the RNA 
sample. These techniques are used for the amplification 
of RNA in order to check for a viral load or genotype 
[13-21]. Some studies have shown that the performance 
of the DBS can be optimized in the laboratory from 
whole blood in the tube. 
3. Limits 
Blood samples are collected on the DBS of the order of 
50 to 100 µl of blood (or plasma) or 1 to 2 drops per spot. 
This is enough for some analysis on DNA in general 
[16,22], but may be insufficient for the analysis of viral 
RNA if the viral load is low, less than 1000 copies/mL or 
a of 3.0 log viral load [12-53]. The disadvantage of DBS 
is often associated with small amounts of blood collected 
available for testing, and the difficulties encountered in 
laboratories in order to extract the maximum possible 
material without contamination [12,16]. Indeed, the ex- 
traction of DNA and RNA on DBS protocols are more 
laborious and longer than the extraction of blood (or its 
derivatives) liquids [12,16], it is for most protocols modi- 
fied to optimize the performance results of this support. 
The quality of the filter paper used also plays an impor- 
tant role in the collection of samples [10,23]. 
4. Storage Conditions 
DBS can be stored at room temperature (25˚C - 35˚C) in 
a refrigerator at 4˚C in a freezer at −20˚C or even in a 
freezer at −70˚C. After collection of the samples, DBS 
must be properly dried and packaged to prevent con- 
tamination, and placed in a safe place for its preservation. 
It is recommended to leave the DBS to dry for a little 
more than 1 hour (1 to 12 hours of drying) at room tem- 
perature before storing. One study showed a longer dry- 
ing (18 - 24 hours) away from light does not affect the 
quality of the final performance of the sample [12,24]. 
DBS stored at room temperature can remain stable for 
optimum performance up to an average of 14 days (2 
weeks) before starting to lose the quality of material that 
are deposited [12,16,25]. Bertagnolio et al., and Wallis et 
al. reported a good (90%) amplification efficiency after 
storage for 3 months at ambient temperature with a hu- 
midity of 85% [12,16,26,27], and Ziemniak et al. have 
published comparable performance on DBS stored at 
room temperature for about 5 months for genotyping [12, 
28]. Nelson et al. found a yield of 69% and a decrease of 
log10 viral load with DBS stored at room temperature for 
3 to 6 years [12,29]. At 4˚C, it retains up to 12 months 
without loss of performance [12,27,30]. In a freezer 
(−20˚C) or a deep-freezer (−70˚C), it will keep for sev- 
eral years while maintaining a similar during the initial 
sampling [12,16,31] quality. This material sample collec- 
tion is relatively stable in these conditions. The ideal sto- 
rage temperature therefore depends on the use to which 
the equipment is intended over time. 
Storage in extreme conditions (above 37˚C with 100% 
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humidity) causes a significant decrease in the quality of 
genetic material more prolonged exposure, the quality 
decline [32]. Exposure in these conditions over 2 weeks 
significantly decrease the quality and quantity of extract- 
ed DNA, and make it difficult to extract RNA [27,32]. 
5. DBS, Diagnosis and Viral Load 
By qualitative or quantitative PCR, several research teams 
have shown that DBS and its variants (DPS and DSS), 
are suitable materials for the diagnosis of patients with 
HIV infection and virological monitoring [12,16]. It is 
even recommended by WHO for the early diagnosis of 
children born to HIV-positive mothers in the world, but 
especially in Africa where the rate of vertical transmis- 
sion is not very well controlled [12]. It has been proven 
for monitoring HIV patients in resources limited settings 
in different countries [8,9,11,12,17,24,27,33-42]. 
For the diagnosis of HIV-1 qualitative PCR, the sensi-
tivity of DBS is 100% when stored according to good 
standards [12,16]. Detection by qualitative PCR on RNA 
or proviral DNA gave identical to those obtained from 
whole blood, buffy coat, serum or plasma results even 
when stored under ideal conditions. With less than 1000 
copies/ml of viral load, qualitative PCR on RNA DBS 
loses its sensitivity (58% - 80%) depending on the techni- 
ques used [12,16,22,26,28,31,43]. 
For Viral Load, the sensitivity and specificity of this 
support are more than 98% for greater than 5000 copies 
per milliliter loads. Between 1000 and 4000 copies/ml, 
the sensitivity of quantification is lost, it varies between 
80% and 98% if the storage conditions are ideal. For less 
than 1000 copies/ml of viral load, the sensitivity is 58% 
to 80% for matches with the plasma [12,16,22,24,26,28, 
31,38,43-47]. 
It is therefore an essential tool for the diagnosis of 
HIV infection and monitoring of patients with greater 
than 1000 copies/ml, provided they meet the conditions 
of storage for viral load tools. 
DBS has also been used in serology for p24 antigen 
and for the enumeration of CD4 T-cells [2,48]. Blood 
components are not affected by the paper and drying al- 
though it is fragile and heat. 
6. DBS and Genotyping 
Recently, DBS was evaluated for genotyping tests. The 
results were very convincing with correlation coefficient 
of amplification of more than 90% using samples of va- 
rious origins [12,16,22,26,28,30,31,36,43,49-53]. Several 
kits sequencing were used to confirm its use for geno- 
typing with great success in more than 80% success rate. 
All studies reported a high correlation between the 
changes in resistance of the material collected in the pla- 
sma and that the DBS, with a nucleotide correlation up to 
99.95% [12,16,22,26,28,30,31,36,43,49]. As for the quan- 
titative PCR, the efficiency of amplification for genotyp- 
ing down with samples that have less than 1000 copies/ 
ml of viral load [12,16,22,26,30,31,43]. But this decrease 
does not affect the quality of material that can be ex- 
tracted [12,16,22,26,30,31,43]. 
There is potential interference of proviral DNA and 
viral RNA during genotypic [12,16,22,28,31]. Some mu- 
tations archived in proviral DNA can alter the pattern of 
results in the analysis for mutations in the initiation of 
treatment or during sero-surveillance [12,22,28,31]. This 
is why some teams have developed the use of DSS or 
DPS for genotyping of RNA [13,15,17]. There is less 
possibility of finding DNA with DSS or DPS. 
For genotyping, genetic material is better preserved on 
the DBS when stored at 4˚C [30]. It is possible to find the 
same consistency from genetic material extracted one 
year after removal of the medium kept at 4˚C. 
7. Conclusion 
DBS is a handy material for the collection, transport and 
analyses of biological monitoring of HIV infection. It re- 
duces the amount of blood required per sample for pa- 
tients. It is less invasive and easier to carry. It is easy to 
keep under ambient conditions. It has been tested under 
different conditions and gives results consistent surpris- 
ing. DBS can be used for the diagnosis of HIV, to assess 
the viral load, CD4 T-cells counts, and even for genoty- 
ping and monitoring of resistance. It is indeed very suit- 
able for environments with limited accessibility, where it 
is difficult for specialized laboratories to monitor these 
patients. DBS is suitable for resource-limited settings. 
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